Literature DB >> 10979130

Velocardiofacial syndrome: incidence of immune cytopenias.

S G Duke1, W F McGuirt, T Jewett, M B Fasano.   

Abstract

BACKGROUND: Velocardiofacial syndrome (VCFS) is associated with a broad clinical spectrum that frequently overlaps the DiGeorge syndrome. Both have been linked to chromosomal microdeletions of chromosome 22 (22q11.2). DiGeorge syndrome is associated with T-cell dysfunction. What is the incidence of immune cytopenias in children with VCFS?
OBJECTIVES: To (1) identify, (2) characterize, (3) quantify, and (4) follow up the immunologic deficits in children initially seen in our institution with VCFS.
DESIGN: Prospective clinical evaluation of patients with the features of VCFS. PATIENTS: Twenty consecutive children with the clinical diagnoses of VCFS.
SETTING: Tertiary care children's hospital. MAIN OUTCOME MEASURES: All 20 children had genetics evaluation with chromosomal analysis. Immunologic evaluations included serum immunoglobulin concentrations, lymphocyte studies, and mitogen and antigen stimulation studies.
RESULTS: Five (25%) of 20 children were noted to have T-cell dysfunction with a clinical presentation marked by recurrent upper respiratory tract infections. Three of these 5 children had resolution of the T-cell dysfunction over a 2-year period. The 2 children with persistent cytopenias combined with immunoglobulin dysfunction required intravenous IgG infusions to control their infections.
CONCLUSIONS: Velocardiofacial syndrome is associated with an increased incidence of immune cytopenias and, thus, warrants evaluation in any child with the clinical diagnosis of VCFS. This immune deficit may be transient and depends on the age of the evaluation of the child.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10979130     DOI: 10.1001/archotol.126.9.1141

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  7 in total

1.  Secondary immunologic consequences in chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome).

Authors:  R Zemble; E Luning Prak; K McDonald; D McDonald-McGinn; E Zackai; K Sullivan
Journal:  Clin Immunol       Date:  2010-05-15       Impact factor: 3.969

Review 2.  Thymus transplantation.

Authors:  M Louise Markert; Blythe H Devlin; Elizabeth A McCarthy
Journal:  Clin Immunol       Date:  2010-03-16       Impact factor: 3.969

Review 3.  DiGeorge syndrome/chromosome 22q11.2 deletion syndrome.

Authors:  K E Sullivan
Journal:  Curr Allergy Asthma Rep       Date:  2001-09       Impact factor: 4.806

4.  Review of 54 patients with complete DiGeorge anomaly enrolled in protocols for thymus transplantation: outcome of 44 consecutive transplants.

Authors:  M Louise Markert; Blythe H Devlin; Marilyn J Alexieff; Jie Li; Elizabeth A McCarthy; Stephanie E Gupton; Ivan K Chinn; Laura P Hale; Thomas B Kepler; Min He; Marcella Sarzotti; Michael A Skinner; Henry E Rice; Jeffrey C Hoehner
Journal:  Blood       Date:  2007-02-06       Impact factor: 22.113

5.  Impact of 22q11.2 deletion on the postoperative course of children after cardiac surgery.

Authors:  Rachel McDonald; Andrew Dodgen; Sunali Goyal; Jeffrey M Gossett; Takeshi Shinkawa; Santosh C Uppu; Carlos Blanco; Xiomara Garcia; Adnan T Bhutta; Michiaki Imamura; Punkaj Gupta
Journal:  Pediatr Cardiol       Date:  2012-08-03       Impact factor: 1.655

Review 6.  Educational paper: syndromic forms of primary immunodeficiency.

Authors:  Rogier Kersseboom; Alice Brooks; Corry Weemaes
Journal:  Eur J Pediatr       Date:  2011-02-22       Impact factor: 3.183

7.  Congenital Heart Disease as a Warning Sign for the Diagnosis of the 22q11.2 Deletion.

Authors:  Marcília S Grassi; Cristina M A Jacob; Leslie D Kulikowski; Antonio C Pastorino; Roberta L Dutra; Nana Miura; Marcelo B Jatene; Stephanie P Pegler; Chong A Kim; Magda Carneiro-Sampaio
Journal:  Arq Bras Cardiol       Date:  2014-10-10       Impact factor: 2.000

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.